Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JUNE 2017. Refer to TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | blinatumomab (Blincyto®) | ||
| Formulation | 38.5 microgram/vial powder for concentrate and solution for solution for infusion | ||
| Reference number | 589 | ||
| Indication | Treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia |
||
| Company | Amgen Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 1916 | ||
| NMG meeting date | 08/06/2016 | ||
| AWMSG meeting date | 13/07/2016 | ||
| Ratification by Welsh Government | 26/07/2016 | ||
| Date of issue | 27/07/2016 | ||
| NICE guidance | TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (external website - opens in new window) |
||